| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| June 20, 2014 | CMO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 50,000 | -- | 175,550 | |
| March 15, 2006 | EVP-COO, CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 20,000 | -- | 176,334 | |
| May 30, 2017 | Director, Chairman, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 176,429 | -- | 176,429 | |
| July 18, 2022 | Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 177,000 | -- | 177,000 | |
| March 19, 2021 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 179,737 | |
| February 21, 2017 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 35,000 | $0.23 | 180,081 | |
| March 19, 2021 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 180,118 | |
| August 16, 2013 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,000 | $1.07 | 180,375 | |
| June 9, 2004 | Exec. VP, Chief Operating Off. | Form 4 | Open market or private purchase of non-derivative or derivative security | 30,000 | $0.70 | 181,667 | |
| March 19, 2021 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 183,689 | |
| February 27, 2012 | Senior Vice President | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 13,750 | -- | 183,750 | |
| February 19, 2010 | Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | $2.94 | 185,000 | |
| February 25, 2020 | Director, Chairman, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 155,000 | $1.16 | 187,700 | |
| June 15, 2020 | CFO | Form 4 | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 250,000 | -- | 189,951 | |
| September 14, 2012 | CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 3,100 | $5.03 | 194,114 | |
| September 14, 2012 | CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 1,900 | $5.04 | 196,014 | |
| May 26, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 34,542 | $2.77 | 197,104 | |
| January 16, 2006 | VP of Clinical Development | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 200,000 | -- | 200,000 | |
| June 9, 2004 | Vice President,General Counsel | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 200,000 | -- | 200,000 | |
| May 6, 2013 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 35,000 | -- | 205,000 | |
| November 16, 2005 | EVP, CFO | Form 4/A | Open market or private purchase of non-derivative or derivative security | 3,700 | $0.29 | 210,367 | |
| December 7, 2012 | President & CEO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 17,271 | $2.77 | 213,285 | |
| March 19, 2021 | Controller | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 65,000 | -- | 214,557 | |
| March 17, 2023 | Director, Executive Chairman of Board | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 25,000 | -- | 215,846 | |
| February 22, 2005 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 55,000 | -- | 216,000 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.
